Visual acuity a multifactorial metric

Article

Although image quality has a clear influence on visual acuity, it does not account for all the individual variability of other factors that must be involved including, measurement errors, or wavefront, optical or neural factors, Raymond Applegate said.

Although image quality has a clear influence on visual acuity, it does not account for all the individual variability of other factors that must be involved including, measurement errors, or wavefront, optical or neural factors, Raymond Applegate said.

Wavefront factors could include visual performance, while optical factors include issues like scatter or chromatic aberration. Neural factors include cone sampling, internal noise and cognitive issues, he remarked.

"In eyes with normal to excellent photopic high contrast (P HC) acuity, optical quality metrics increase in predictive value with increasing difficulty of the visual task," he said.

The more difficult the task, the more detailed and refined the ultimate visual acuity measurement will be. In the case of normal healthy eyes, high photopic stimuli makes P HC acuity insensitive to minor variations in wavefront error. As such, it's a less accurate metric.

For example, higher order aberrations (HOA) account for only 4% of the variance in photopic high contrast acuity. That means, only 4% of HOAs are detected. "In comparison, mesopic low contrast (M LC) acuity is eight times more sensitive than photopic high contrast acuity to the same variation in optical quality accounting for 37% of the variance in acuity."

Mesopic low contrast stimuli contain less redundant information and are therefore more sensitive to minor variations in image quality.

In a clinical environment the effect of minor variations on optical quality can be assessed with mesopic low contrast acuity, but not with photopic high contrast acuity, Dr Applegate noted.

Ophthalmology Times Europe reporting from the XXIV Congress of the ESCRS, London, 9-13 September, 2006.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.